A298380 Stock Overview
A biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ABL Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩27,550.00 |
| 52 Week High | ₩38,500.00 |
| 52 Week Low | ₩15,370.00 |
| Beta | 1.15 |
| 11 Month Change | 1.66% |
| 3 Month Change | 10.42% |
| 1 Year Change | 52.63% |
| 33 Year Change | 33.41% |
| 5 Year Change | 49.73% |
| Change since IPO | 101.83% |
Recent News & Updates
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29
Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26Recent updates
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth
Mar 31Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?
Jan 20
Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth
Dec 16Shareholder Returns
| A298380 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -18.9% | -5.4% | -3.5% |
| 1Y | 52.6% | 28.7% | -2.4% |
Return vs Industry: A298380 exceeded the KR Biotechs industry which returned 28.1% over the past year.
Return vs Market: A298380 exceeded the KR Market which returned -2.7% over the past year.
Price Volatility
| A298380 volatility | |
|---|---|
| A298380 Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A298380's share price has been volatile over the past 3 months.
Volatility Over Time: A298380's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 102 | Sang Hoon Lee | www.ablbio.com |
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea.
ABL Bio Inc. Fundamentals Summary
| A298380 fundamental statistics | |
|---|---|
| Market cap | ₩1.32t |
| Earnings (TTM) | -₩40.00b |
| Revenue (TTM) | ₩32.95b |
40.2x
P/S Ratio-33.1x
P/E RatioIs A298380 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A298380 income statement (TTM) | |
|---|---|
| Revenue | ₩32.95b |
| Cost of Revenue | ₩62.74m |
| Gross Profit | ₩32.89b |
| Other Expenses | ₩72.89b |
| Earnings | -₩40.00b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -832.56 |
| Gross Margin | 99.81% |
| Net Profit Margin | -121.39% |
| Debt/Equity Ratio | 80.9% |
How did A298380 perform over the long term?
See historical performance and comparison